Data from EMC - Curated by Toby Galbraith - Last updated 10 May 2017

Licensing authority

EMA (European Medicines Agency)


Movymia is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure


Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism

More information

Category Value
Agency product number EMEA/H/C/004368
Orphan designation No
Date First Approved 11-01-2017
Type POM
Marketing authorisation holder STADA Arzneimittel AG

Related Content